Close
  Indian J Med Microbiol
 

Figure 2: Proposed pathway for hydrogen (H2) therapy and its downstream targets. Note: VEGF: Vascular endothelial growth factor; MAK: serine/threonine-protein kinase; ERK1/2: extracellular signal-regulated kinase 1/2; cGMP: cyclic guanosine monophosphate; PDE: phosphodiesterases; PKG: protein kinase G; eNOS: endothelial nitric oxide synthase; NO2: nitrogen dioxide; sGC: solubleguanylatecyclase; IL: interleukin; TNF: tumor necrosis factor; ICAM-1: intercellular cell adhesion molecule-1; HMGB-1: high-mobility group box protein 1.

Figure 2: Proposed pathway for hydrogen (H<sub>2</sub>) therapy and its downstream targets.
Note: VEGF: Vascular endothelial growth factor; MAK: serine/threonine-protein kinase; ERK1/2: extracellular signal-regulated kinase 1/2; cGMP: cyclic guanosine monophosphate; PDE: phosphodiesterases; PKG: protein kinase G; eNOS: endothelial nitric oxide synthase; NO<sub>2</sub>: nitrogen dioxide; sGC: solubleguanylatecyclase; IL: interleukin; TNF: tumor necrosis factor; ICAM-1: intercellular cell adhesion molecule-1; HMGB-1: high-mobility group box protein 1.